MONTPELLIER

CGI opens new global innovation center dedicated to Industry 4.0 in Toulouse, France

Retrieved on: 
Jeudi, octobre 21, 2021
Commerce, Human voice, Automation, Technology, La Crosse Center, Industry, GIB, Goal, Organization, NYSE, CGI, TSX, Consultant, Senior, Internet, Lyon, System, IOT, Fourth Industrial Revolution, Solution, Heart, Mining, Entertainment, Sales

TOULOUSE, France, Oct. 21, 2021 /PRNewswire/ - CGI (NYSE: GIB) (TSX: GIB.A) has opened a new global innovation center dedicated to Industry 4.0 in the heart of the Occitanie region in Toulouse, France.

Key Points: 
  • TOULOUSE, France, Oct. 21, 2021 /PRNewswire/ - CGI (NYSE: GIB) (TSX: GIB.A) has opened a new global innovation center dedicated to Industry 4.0 in the heart of the Occitanie region in Toulouse, France.
  • This latest center completes a network of global innovation centers established by CGI in France, including centers dedicated to digital transformation (Montpellier), commerce and consumer services (Lille) and supply chain digitization (Lyon).
  • CGI's new global innovation center is designed to help manufacturers achieve these goals and more.
  • CGI Fiscal 2020 reported revenue is C$12.16 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB).

DGAP-News: ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

Retrieved on: 
Lundi, octobre 18, 2021
EMA, Cancer, Ulcerative colitis, European Medicines Agency, ISIN, Hepatocellular carcinoma, JAK, PP, FDA, Volunteering, Patient, Abivax, UC, ITT, Twitter, Maintenance, Safety, Degenerative disease, Pharmaceutical industry, Medical device

During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.

Key Points: 
  • During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.
  • In May and September 2021, Abivax already announced the top-line and full results , respectively, of this randomized, placebo-controlled phase 2b trial of ABX464 in moderate to severe ulcerative colitis patients following induction treatment.
  • 254 patients with moderate to severe active ulcerative colitis were enrolled in this phase 2b trial and randomized to three once-daily oral ABX464 treatment groups (25mg, 50mg and 100mg) or placebo.
  • In addition to the phase 2b maintenance results, Abivax recently also reported efficacy data from its ongoing phase 2a maintenance study in UC.

DGAP-News: Abivax announces the release of its 2021 half-year financial report

Retrieved on: 
Jeudi, septembre 30, 2021
ISIN, CEST, Abivax, Euronext Paris, Cancer, Patient, AMF, Immune system, Twitter, Hepatocellular carcinoma, Degenerative disease, Pharmaceutical industry

PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report.

Key Points: 
  • PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report.
  • This document is available in electronic version on the website of the company ( www.abivax.com - "Investors" ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ).
  • Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

DGAP-News: Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021

Retrieved on: 
Mardi, septembre 28, 2021
ISIN, IBD, UC, Icahn School of Medicine at Mount Sinai, Cancer, Patient, Mount Sinai, Q&A, Twitter, CA, University, UEG, Hepatocellular carcinoma, MicroRNA, Degenerative disease, UZ Leuven, Pharmaceutical industry

, of the Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Key Points: 
  • , of the Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Following the presentations, participants will have the opportunity to ask questions during the live Q&A session.
  • Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnmo: ABVX).
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.